Ramirez-Falcon Melody, Suarez-Pajes Eva, Flores Carlos
Research Unit, Hospital Universitario Ntra. Sra. de Candelaria, Instituto de Investigación Sanitaria de Canarias, 38010 Santa Cruz de Tenerife, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Int J Mol Sci. 2024 Dec 19;25(24):13611. doi: 10.3390/ijms252413611.
Since their discovery, corticosteroids have been widely used in the treatment of several diseases, including asthma, acute lymphoblastic leukemia, chronic obstructive pulmonary disease, and many other conditions. However, it has been noted that some patients develop undesired side effects or even fail to respond to treatment. The reasons behind this have not yet been fully elucidated. This poses a significant challenge to effective treatment that needs to be addressed urgently. Recent genomic, transcriptomic, and other omics-based approximations have begun to shed light into the genetic factors influencing interindividual variability in corticosteroid efficacy and its side effects. Here, we comprehensively revise the recent literature on corticosteroid response in various critical and chronic diseases, with a focus on omics approaches, and highlight existing knowledge gaps where further investigation is urgently needed.
自发现以来,皮质类固醇已广泛用于治疗多种疾病,包括哮喘、急性淋巴细胞白血病、慢性阻塞性肺疾病以及许多其他病症。然而,已经注意到一些患者会出现不良副作用,甚至对治疗无反应。其背后的原因尚未完全阐明。这对需要紧急解决的有效治疗构成了重大挑战。最近基于基因组学、转录组学和其他组学的研究方法已开始揭示影响皮质类固醇疗效个体差异及其副作用的遗传因素。在此,我们全面回顾了近期关于各种重症和慢性疾病中皮质类固醇反应的文献,重点关注组学方法,并突出了迫切需要进一步研究的现有知识空白。